Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.

Key Points

• This research aims to evaluate the effects of sodium-glucose cotransporter 2 inhibitors on kidney diseases unrelated to diabetes.
• Assessment of SGLT2 inhibitors in a population with chronic kidney disease.
• Comparison of renal outcomes in patients with and without diabetes.
• Focus on benefits attributed specifically to immunoglobulin A nephropathy.
• SGLT2 inhibitors show positive effects on composite renal outcomes.
• Benefits appear to be significantly influenced by immunoglobulin A nephropathy.
• Improvements in kidney function noted across various patient groups, regardless of diabetes status.